Case study: three acute 241Am inhalation exposures with DTPA therapy.
Three workers incurred inhalation exposures to Am oxide as a result of waste sorting and compaction activities. The exposure magnitudes were not fully recognized until the following day when an in-vivo lung count identified a significant lung deposition of Am in a male worker, and DTPA chelation therapy was initiated. Two additional workers (one female and one male) were then identified as sufficiently exposed to also warrant therapy. In-vivo bioassay measurements were performed over the ensuing 6 mo to quantify the 241Am activity in the lungs, liver, and skeleton. Urine and fecal samples were collected and showed readily detectable 241Am. Clinical lab tests and medical evaluations all showed normal results. There were no significant adverse clinical health effects from the therapy. The estimated 241Am inhalation intakes for the three workers were 1,800 Bq, 630 Bq, and 150 Bq. Lung retention showed somewhat longer pulmonary clearance half-times than standard inhalation class W or absorption Type M assumptions. The three subjects underwent slightly different therapy regimens, with therapy effectiveness factors (defined as the ratio of the reference doses without therapy relative to the final assessed doses) of 4.5, 1.9, and 1.7, respectively.
Carbaugh
Eugene H
EH
Battelle-Pacific Northwest Division, Richland, WA 99352, USA. gene.carbaugh@pnl.gov
Lynch
Timothy P
TP
Cannon
Curt N
CN
Lewis
Loren L
LL
D000328:Adult; D000576:Americium / Q000032:analysis / Q000493:pharmacokinetics* / Q000652:urine; D001681:Biological Assay; D001822:Body Burden; D002614:Chelating Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003666:Decontamination; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000737:chemistry; D005260:Female; D006801:Humans; D019570:Inhalation Exposure; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008297:Male; D016273:Occupational Exposure; D004369:Pentetic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D011832:Radiation Injuries / Q000378:metabolism / Q000517:prevention & control; D012062:Relative Biological Effectiveness; D013997:Time Factors; D016896:Treatment Outcome
D002614:Chelating Agents; D004369:Pentetic Acid; D000576:Americium